Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.
Jeffrey R. Infante, MD
Advertisement
Articles by Jeffrey R. Infante, MD
Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.
Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research
Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma
Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
Advertisement
Latest Updated Articles
Dr. Infante on the Future of BRAF Inhibitors in MelanomaPublished: June 8th 2011 | Updated:
Dr. Infante on the Next Step in Melanoma ResearchPublished: June 23rd 2011 | Updated:
Dr. Infante on Avelumab's Potential in Ovarian CancerPublished: July 22nd 2015 | Updated:
Dr. Infante on AM0010 in Patients With RCCPublished: May 11th 2016 | Updated:
Dr. Infante Talks About BRAF Mutation TestingPublished: June 7th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5